Cited by 205Fungal Infections and StudiesAntifungal resistance and susceptibilityFungal Plant Pathogen Control

The DOI matches its Crossref record; 43 of the 44 references it cites were found in a registry or an index.

The Antidepressant Sertraline Provides a Promising Therapeutic Option for Neurotropic Cryptococcal Infections

Open access

Zhai, Bing, Wu, Cheng, Wang, Linqi, Sachs, Matthew S., Lin, Xiaorong·2012·Antimicrobial Agents and Chemotherapy

Open this paper in CoChat — free account Open PDF

Abstract

Therapeutic treatment for systemic mycoses is severely hampered by the extremely limited number of antifungals. The difficulty of treatment of fungal infections in the central nervous system is further compounded by the poor central nervous system (CNS) penetration of most antifungals due to the blood-brain barrier. Only a few fungistatic azole drugs, such as fluconazole, show reasonable CNS penetration. Here we demonstrate that sertraline (Zoloft), the most frequently prescribed antidepressant, displays potent antifungal activity against Cryptococcus neoformans , the major causative agent of fungal meningitis. In in vitro assays, this neurotropic drug is fungicidal to all natural Cryptococcus isolates tested at clinically relevant concentrations. Furthermore, sertraline interacts synergistically or additively with fluconazole against Cryptococcus . Importantly, consistent with our in vitro observations, sertraline used alone reduces the brain fungal burden at an efficacy comparable to that of fluconazole in a murine model of systemic cryptococcosis. It works synergistically with fluconazole in reducing the fungal burden in brain, kidney, and spleen. In contrast to its potency against Cryptococcus , sertraline is less effective against strains of Candida species and its interactions with fluconazole against Candida strains are often antagonistic. Therefore, our data suggest the unique application of sertraline against cryptococcosis. To understand the antifungal mechanisms of sertraline, we screened a whole-genome deletion collection of Saccharomyces cerevisiae for altered sertraline susceptibility. Gene ontology analyses of selected mutations suggest that sertraline perturbs translation. In vitro translation assays using fungal cell extracts show that sertraline inhibits protein synthesis. Taken together, our findings indicate the potential of adopting this antidepressant in treating cryptococcal meningitis.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1128/aac.00212-12

Cites

43 of 43 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Functional Characterization of the S. cerevisiae Genome by Gene Deletion and Parallel Analysis
Winzeler, E. A., Shoemaker, D. D., Astromoff, A., Liang, H., Anderson, K., Andre, B., Bangham, R., Benito, R., Boeke, J. D., Bussey, H., et al. (1999) · Science · doi:10.1126/science.285.5429.901 · Cited by 3,953
Clinical Practice Guidelines for the Management of Cryptococcal Disease: 2010 Update by the Infectious Diseases Society of America
Perfect, J. R., Dismukes, W. E., Dromer, F., Goldman, D. L., Graybill, J. R., Hamill, R. J., Harrison, T. S., Larsen, R. A., Lortholary, O., Nguyen, M.-H., et al. (2010) · Clinical Infectious Diseases · doi:10.1086/649858 · Cited by 2,660
Estimation of the current global burden of cryptococcal meningitis among persons living with HIV/AIDS
Park, B. J., Wannemuehler, K. A., Marston, B. J., Govender, N. P., Pappas, P. G., & Chiller, T. M. (2009) · AIDS · doi:10.1097/qad.0b013e328322ffac · Cited by 2,062
Recent findings on the viable but nonculturable state in pathogenic bacteria.
Oliver, J. (2010) · FEMS Microbiology Reviews · doi:10.1111/j.1574-6976.2009.00200.x · Cited by 1,231
Cryptococcosis in the era of AIDS--100 years after the discovery of Cryptococcus neoformans
Mitchell, T. G., & Perfect, J. R. (1995) · Clinical Microbiology Reviews · doi:10.1128/cmr.8.4.515 · Cited by 1,213
Pharmacokinetics of selective serotonin reuptake inhibitors
Hiemke, C., & Härtter, S. (2000) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(99)00048-0 · Cited by 887
Amphotericin B: side effects and toxicity
Laniado-Laborín, R., & Cabrales-Vargas, M. N. (2009) · Revista Iberoamericana de Micología · doi:10.1016/j.riam.2009.06.003 · Cited by 739
Cryptococcus neoformans
Casadevall, A., & Perfect, J. R. (1998) · ASM Press eBooks · doi:10.1128/9781555818241 · Cited by 697
Drug and chemical blood-level data 2001
Winek, C. L., Wahba, W. W., Winek, C. L., & Winek, T. A. (2001) · Forensic Science International · doi:10.1016/s0379-0738(01)00483-2 · Cited by 367
Identifying off-target effects and hidden phenotypes of drugs in human cells
MacDonald, M. L., Lamerdin, J. E., Owens, S., Keon, B. H., Bilter, G. K., Shang, Z., Huang, Z., Yu, H. W., Dias, J., Minami, T., et al. (2006) · Nature Chemical Biology · doi:10.1038/nchembio790 · Cited by 294

Flagged first, then by citations

Show all 44 references

1 of the 44 references couldn’t be matched to a known paper.

Sorted by citations

The antifungal pipeline: a reality check
Perfect, J. R. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.46 · Cited by 866
Antifungal Drug Development: Challenges, Unmet Clinical Needs, and New Approaches
Roemer, T., & Krysan, D. J. (2014) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a019703 · Cited by 593
Cryptococcus: from environmental saprophyte to global pathogen
May, R. C., Stone, N. R. H., Wiesner, D. L., Bicanic, T., & Nielsen, K. (2016) · Nature Reviews Microbiology · doi:10.1038/nrmicro.2015.6 · Cited by 541
The Still Underestimated Problem of Fungal Diseases Worldwide
Almeida, F. B. D. R., Rodrigues, M. L., & Coelho, C. (2019) · Frontiers in Microbiology · doi:10.3389/fmicb.2019.00214 · Cited by 452
A novel mechanism of generating extracellular vesicles during apoptosis via a beads-on-a-string membrane structure
Atkin‐Smith, G. K., Tixeira, R., Paone, S., Mathivanan, S., Collins, C., Liem, M. K., Goodall, K. J., Ravichandran, K. S., Hulett, M. D., & Poon, I. K. H. (2015) · Nature Communications · doi:10.1038/ncomms8439 · Cited by 409
Drug repurposing for antimicrobial discovery
Farha, M. A., & Brown, E. D. (2019) · Nature Microbiology · doi:10.1038/s41564-019-0357-1 · Cited by 382
Treatment strategies for cryptococcal infection: challenges, advances and future outlook
Iyer, K. R., Revie, N. M., Fu, C., Robbins, N., & Cowen, L. E. (2021) · Nature Reviews Microbiology · doi:10.1038/s41579-021-00511-0 · Cited by 363
Antifungal tolerance is a subpopulation effect distinct from resistance and is associated with persistent candidemia
Rosenberg, A., Ene, I. V., Bibi, M., Zakin, S., Segal, E. S., Ziv, N., Dahan, A. M., Colombo, A. L., Bennett, R. J., & Berman, J. (2018) · Nature Communications · doi:10.1038/s41467-018-04926-x · Cited by 270
Antifungal Drugs: The Current Armamentarium and Development of New Agents
Robbins, N., Wright, G. D., & Cowen, L. E. (2016) · Microbiology Spectrum · doi:10.1128/microbiolspec.funk-0002-2016 · Cited by 271
Drug repositioning: Progress and challenges in drug discovery for various diseases
Hua, Y., Dai, X., Xu, Y., Xing, G., Liu, H., Lu, T., Chen, Y., & Zhang, Y. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.114239 · Cited by 232
Combinatorial strategies for combating invasive fungal infections
Spitzer, M., Robbins, N., & Wright, G. D. (2016) · Virulence · doi:10.1080/21505594.2016.1196300 · Cited by 227
New Horizons in Antifungal Therapy
Pianalto, K. M., & Alspaugh, J. A. (2016) · Journal of Fungi · doi:10.3390/jof2040026 · Cited by 197
Increased Antifungal Drug Resistance in Clinical Isolates of Cryptococcus neoformans in Uganda
Smith, K. D., Achan, B., Hullsiek, K. H., McDonald, T. R., Okagaki, L. H., Alhadab, A. A., Akampurira, A., Rhein, J., Meya, D. B., Boulware, D. R., et al. (2015) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01299-15 · Cited by 191
Immunomodulatory Effects Mediated by Serotonin
Arreola, R., Becerril‐Villanueva, E., Cruz-Fuentes, C. S., Velasco-Velázquez, M. A., Garcés-Alvarez, M. E., Hurtado‐Alvarado, G., Quintero-Fabián, S., & Pavón, L. (2015) · Journal of Immunology Research · doi:10.1155/2015/354957 · Cited by 198
Efficacy of adjunctive sertraline for the treatment of HIV-associated cryptococcal meningitis: An open-label dose-ranging study
Rhein, J., Morawski, B. M., Hullsiek, K. H., Nabeta, H. W., Kiggundu, R., Tugume, L., Musubire, A., Akampurira, A., Smith, K. D., Alhadab, A., et al. (2016) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(16)00074-8 · Cited by 183
Antifungal Drug Discovery: Something Old and Something New
Butts, A., & Krysan, D. J. (2012) · PLoS Pathogens · doi:10.1371/journal.ppat.1002870 · Cited by 182
Current Antimycotics, New Prospects, and Future Approaches to Antifungal Therapy
Wall, G., & Lopez-Ribot, J. L. (2020) · Antibiotics · doi:10.3390/antibiotics9080445 · Cited by 183
Cryptococcal Meningitis: Diagnosis and Management Update
Abassi, M., Boulware, D. R., & Rhein, J. (2015) · Current Tropical Medicine Reports · doi:10.1007/s40475-015-0046-y · Cited by 179
Psychotropics and the Microbiome: a Chamber of Secrets…
Cussotto, S., Clarke, G. A., Dinan, T. G., & Cryan, J. F. (2019) · Psychopharmacology · doi:10.1007/s00213-019-5185-8 · Cited by 176
Antifungal drugs: New insights in research & development
Nicola, A. M., Albuquerque, P., Paes, H. C., Fernandes, L., Costa, F. F., Kioshima, É. S., Abadio, A. K. R., Bocca, A. L., & Felipe, M. S. S. (2018) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.10.008 · Cited by 152
Combatting the evolution of antifungal resistance in Cryptococcus neoformans
Bermas, A., & Geddes‐McAlister, J. (2020) · Molecular Microbiology · doi:10.1111/mmi.14565 · Cited by 143
The Future of Antifungal Drug Therapy: Novel Compounds and Targets
Mota Fernandes, C., Dasilva, D., Haranahalli, K., McCarthy, J. B., Mallamo, J., Ojima, I., & Del Poeta, M. (2021) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01719-20 · Cited by 124
Adjunctive sertraline for HIV-associated cryptococcal meningitis: a randomised, placebo-controlled, double-blind phase 3 trial
Rhein, J., Hullsiek, K. H., Tugume, L., Nuwagira, E., Mpoza, E., Evans, E. E., Kiggundu, R., Pastick, K. A., Ssebambulidde, K., Akampurira, A., et al. (2019) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(19)30127-6 · Cited by 124
Diagnosis and treatment of invasive fungal infections: looking ahead
Sanguinetti, M., Posteraro, B., Beigelman‐Aubry, C., Lamoth, F., Dunet, V., Slavin, M. A., & Richardson, M. D. (2019) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkz041 · Cited by 119
Fungal Diseases in the 21st Century: The Near and Far Horizons
Gardiner, E. S., & Stanturf, J. A. (2018) · REFORESTA · doi:10.20411/pai.v3i2.249 · Cited by 112
Emerging novel and antimicrobial-resistant respiratory tract infections: new drug development and therapeutic options
Zumla, A. I., Memish, Z. A., Maeurer, M. J., Bates, M., Mwaba, P., Al‐Tawfiq, J. A., Denning, D. W., Hayden, F. G., & Hui, D. S. C. (2014) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(14)70828-x · Cited by 104
A Repurposing Approach Identifies Off-Patent Drugs with Fungicidal Cryptococcal Activity, a Common Structural Chemotype, and Pharmacological Properties Relevant to the Treatment of Cryptococcosis
Butts, A., DiDone, L., Koselny, K., Baxter, B. K., Chabrier-Rosello, Y., Wellington, M., & Krysan, D. J. (2013) · Eukaryotic Cell · doi:10.1128/ec.00314-12 · Cited by 95
Cryptococcal therapies and drug targets: the old, the new and the promising
Coelho, C., & Casadevall, A. (2016) · Cellular Microbiology · doi:10.1111/cmi.12590 · Cited by 98
The Celecoxib Derivative AR-12 Has Broad-Spectrum Antifungal Activity In Vitro and Improves the Activity of Fluconazole in a Murine Model of Cryptococcosis
Koselny, K., Green, J., DiDone, L., Halterman, J. P., Fothergill, A. W., Wiederhold, N. P., Patterson, T. F., Cushion, M. T., Rappelye, C., Wellington, M., et al. (2016) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01061-16 · Cited by 83
Unraveling the Biology of a Fungal Meningitis Pathogen Using Chemical Genetics
Brown, J. C. S., Nelson, J., VanderSluis, B., Deshpande, R., Butts, A., Kagan, S., Polacheck, I., Krysan, D. J., Myers, C. L., & Madhani, H. D. (2014) · Cell · doi:10.1016/j.cell.2014.10.044 · Cited by 84
Development of Protective Inflammation and Cell-Mediated Immunity against Cryptococcus neoformans after Exposure to Hyphal Mutants
Zhai, B., Wozniak, K. L., Masso-Silva, J. A., Upadhyay, S., Hole, C. R., Rivera, A., Wormley, F. L., & Lin, X. (2015) · mBio · doi:10.1128/mbio.01433-15 · Cited by 79
Self-citation
The Anti-helminthic Compound Mebendazole Has Multiple Antifungal Effects against Cryptococcus neoformans
Joffe, L. S., Schneider, R., Lopes, W., Azevedo, R., Staats, C. C., Kmetzsch, L., Schrank, A., Poeta, M. D., Vainstein, M. H., & Rodrigues, M. L. (2017) · Frontiers in Microbiology · doi:10.3389/fmicb.2017.00535 · Cited by 77
Treatment of Cryptococcal Meningitis: How Have We Got Here and Where are We Going?
Ngan, N. T. T., Flower, B., & Day, J. (2022) · Drugs · doi:10.1007/s40265-022-01757-5 · Cited by 82
Congenic Strains of the Filamentous Form of Cryptococcus neoformans for Studies of Fungal Morphogenesis and Virulence
Zhai, B., Zhu, P., Foyle, D., Upadhyay, S., Idnurm, A., & Lin, X. (2013) · Infection and Immunity · doi:10.1128/iai.00259-13 · Cited by 79
Self-citation
New Approaches for Cryptococcosis Treatment
Spadari, C. D. C., Wirth, F., Lopes, L. B., & Ishida, K. (2020) · Microorganisms · doi:10.3390/microorganisms8040613 · Cited by 79
Sertraline as a promising antifungal agent: inhibition of growth and biofilm of Candida auris with special focus on the mechanism of action in vitro
Gowri, M., Jayashree, B., Jeyakanthan, J., & Girija, E. K. (2019) · Journal of Applied Microbiology · doi:10.1111/jam.14490 · Cited by 76
Immunomodulation as Therapy for Fungal Infection: Are We Closer?
Sam, Q. H., Yew, W. S., Seneviratne, C. J., Chang, M. W., & Chai, L. Y. A. (2018) · Frontiers in Microbiology · doi:10.3389/fmicb.2018.01612 · Cited by 68
Synergistic and antagonistic drug interactions in the treatment of systemic fungal infections
Wambaugh, M. A., Denham, S. T., Ayala, M., Brammer, B., Stonhill, M. A., & Brown, J. C. (2020) · eLife · doi:10.7554/elife.54160 · Cited by 65
“Of those 10, three were reported as synergists but antagonized FLZ activity in our assays (Ahmad et al., 2010; Butts et al., 2014; Cardoso et al., 2016; Eldesouky et al., 2018; Kang et al., 2010; Li et al., 2018; Marchetti et al., 2000; Quan et al., 2006; Robbins et al., 2015; Spitzer et al., 2011; Zhai et al., 2012).”
Background
Activity of sertraline againstCryptococcus neoformans:in vitroandin vivoassays
Treviño‐Rangel, R. D. J., Villanueva‐Lozano, H., Hernández-Rodríguez, P. A., Martínez‐Reséndez, M. F., García‐Juárez, J., Rodríguez‐Rocha, H., & González, G. M. (2015) · Medical Mycology · doi:10.1093/mmy/myv109 · Cited by 65
A complex game of hide and seek: the search for new antifungals
Ngo, H., Garneau‐Tsodikova, S., & Green, K. D. (2016) · MedChemComm · doi:10.1039/c6md00222f · Cited by 66
Treatment for HIV-associated cryptococcal meningitis
Tenforde, M. W., Shapiro, A. E., Rouse, B., Jarvis, J. N., Li, T., Eshun‐Wilson, I., & Ford, N. P. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005647.pub3 · Cited by 66
Confronting antifungal resistance, tolerance, and persistence: advances in drug target discovery and delivery systems
Chen, L., Zhang, L., Xie, Y., Wang, Y., Tian, X., Fang, W., Xue, X., & Wang, L. (2023) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2023.115007 · Cited by 63
Self-citation
New antifungal strategies: Drug combination and co-delivery
Zhu, P., Li, Y., Guo, T., Liu, S., Tancer, R. J., Hu, C., Zhao, C., Xue, C., & Liao, G. (2023) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2023.114874 · Cited by 63
Screening Repurposing Libraries for Identification of Drugs with Novel Antifungal Activity
Wall, G., & Lopez-Ribot, J. L. (2020) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00924-20 · Cited by 67
Present and Future Therapy of Cryptococcus Infections
Mourad, A., & Perfect, J. R. (2018) · Journal of Fungi · doi:10.3390/jof4030079 · Cited by 65
The lncRNA RZE1 Controls Cryptococcal Morphological Transition
Chacko, N., Zhao, Y., Yang, E., Wang, L., Cai, J. J., & Lin, X. (2015) · PLoS Genetics · doi:10.1371/journal.pgen.1005692 · Cited by 60
Self-citation
Diagnosis and Management of Cryptococcal Relapse
Musubire, A. K. (2013) · Journal of AIDS & Clinical Research · doi:10.4172/2155-6113.s3-003 · Cited by 60
Drug Repurposing in Medical Mycology: Identification of Compounds as Potential Antifungals to Overcome the Emergence of Multidrug-Resistant Fungi
Peyclit, L., Yousfi, H., Rolain, J., & Bittar, F. (2021) · Pharmaceuticals · doi:10.3390/ph14050488 · Cited by 58
Platelets and mast cells promote pathogenic eosinophil recruitment during invasive fungal infection via the 5-HIAA-GPR35 ligand-receptor system
Giovanni, M. D., Dang, E. V., Chen, K. Y., An, J., Madhani, H. D., & Cyster, J. G. (2023) · Immunity · doi:10.1016/j.immuni.2023.05.006 · Cited by 55
Antimicrobial Properties of Antidepressants and Antipsychotics—Possibilities and Implications
Caldara, M., & Marmiroli, N. (2021) · Pharmaceuticals · doi:10.3390/ph14090915 · Cited by 54
Repurposing drugs to fast-track therapeutic agents for the treatment of cryptococcosis
Truong, M., Monahan, L. G., Carter, D. A., & Charles, I. G. (2018) · PeerJ · doi:10.7717/peerj.4761 · Cited by 57
An Overview of the Management of the Most Important Invasive Fungal Infections in Patients with Blood Malignancies
Shariati, A., Moradabadi, A., Chegini, Z., Khoshbayan, A., & Didehdar, M. (2020) · Infection and Drug Resistance · doi:10.2147/idr.s254478 · Cited by 58
Atorvastatin as a promising anticryptococcal agent
Ribeiro, N. D. Q., Costa, M. C., Magalhães, T. F. F., Carneiro, H. C. S., Oliveira, L. V., Fontes, A. C. L., Santos, J. R. A., Ferreira, G. F., Araujo, G. R. D. S., Alves, V., et al. (2017) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2017.04.005 · Cited by 51
Repurposing antipsychotic drugs into antifungal agents: Synergistic combinations of azoles and bromperidol derivatives in the treatment of various fungal infections
Holbrook, S. Y. L., Garzan, A., Dennis, E. K., Shrestha, S. K., & Garneau-Tsodikova, S. (2017) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.07.030 · Cited by 51
Toward improved anti-cryptococcal drugs: Novel molecules and repurposed drugs
Krysan, D. J. (2014) · Fungal Genetics and Biology · doi:10.1016/j.fgb.2014.12.001 · Cited by 50
Identification of Off-Patent Drugs That Show Synergism with Amphotericin B or That Present Antifungal Action against Cryptococcus neoformans and Candida spp
Rossi, S. A., de Oliveira, H. C., Agreda-Mellon, D., Lucio, J., Mendes-Giannini, M. J. S., García-Cambero, J. P., & Zaragoza, O. (2020) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01921-19 · Cited by 48
Diagnosis and Management of Central Nervous System Cryptococcal Infections in HIV-Infected Adults
Skipper, C. P., Abassi, M., & Boulware, D. R. (2019) · Journal of Fungi · doi:10.3390/jof5030065 · Cited by 72
Recent drug development and treatments for fungal infections
Roy, M., Karhana, S., Shamsuzzaman, M., & Khan, M. A. (2023) · Brazilian Journal of Microbiology · doi:10.1007/s42770-023-00999-z · Cited by 47
Anti-Candida activity of antidepressants sertraline and fluoxetine: effect upon pre-formed biofilms
Oliveira, A. S., Martinez‐de‐Oliveira, J., Donders, G. G. G., Palmeira‐de‐Oliveira, R., & Palmeira‐de‐Oliveira, A. (2018) · Medical Microbiology and Immunology · doi:10.1007/s00430-018-0539-0 · Cited by 46
Fungicide-tolerant persister formation during cryptococcal pulmonary infection
Ke, W., Xie, Y., Chen, Y., Ding, H., Ye, L., Qiu, H., Li, H., Zhang, L., Chen, L., Tian, X., et al. (2024) · Cell Host & Microbe · doi:10.1016/j.chom.2023.12.012 · Cited by 45
Self-citation
Our current clinical understanding of Candida biofilms: where are we two decades on?
Ramage, G., Borghi, E., Rodrigues, C. F., Kean, R., Williams, C., & Lopez-Ribot, J. L. (2023) · Apmis · doi:10.1111/apm.13310 · Cited by 47
Diagnosis and management of cryptococcal meningitis in HIV-infected adults
McHale, T. C., Boulware, D. R., Kasibante, J., Ssebambulidde, K., Skipper, C. P., & Abassi, M. (2023) · Clinical Microbiology Reviews · doi:10.1128/cmr.00156-22 · Cited by 49
Antifungal Development and the Urgency of Minimizing the Impact of Fungal Diseases on Public Health
de Oliveira, H. C., Bezerra, B. T., & Rodrigues, M. L. (2022) · ACS Bio & Med Chem Au · doi:10.1021/acsbiomedchemau.2c00055 · Cited by 42
In vitro synergistic effects of chlorpromazine and sertraline in combination with amphotericin B against Cryptococcus neoformans var. grubii
Rossato, L. L., Loreto, É. S., Zanette, R. A., Chassot, F., Santúrio, J. M., & Alves, S. H. (2016) · Folia Microbiologica · doi:10.1007/s12223-016-0449-8 · Cited by 39
In Vitro Antifungal Activity of Sertraline and Synergistic Effects in Combination with Antifungal Drugs against Planktonic Forms and Biofilms of Clinical Trichosporon asahii Isolates
Cong, L., Liao, Y., Yang, S., & Yang, R. (2016) · PLoS ONE · doi:10.1371/journal.pone.0167903 · Cited by 39
Seeking the Psilocybiome: Psychedelics meet the microbiota-gut-brain axis
Kelly, J. R., Clarke, G. A., Harkin, A., Corr, S. C., Galvin, S. D., Pradeep, V., Cryan, J. F., O’Keane, V., & Dinan, T. G. (2022) · International Journal of Clinical and Health Psychology · doi:10.1016/j.ijchp.2022.100349 · Cited by 40
Clinical evaluation of the antifungal effect of sertraline in the treatment of cryptococcal meningitis in HIV patients: A single Mexican center experience
Villanueva-Lozano, H., Treviño-Rangel, R. D. J., González, G. M., Hernández-Rodríguez, P. A., Camacho-Ortiz, A., Castillo-Reyna, L., Galindo-Alvarado, S. G., & Martínez-Reséndez, M. F. (2018) · Infection · doi:10.1007/s15010-017-1059-3 · Cited by 35
The RAM signaling pathway links morphology, thermotolerance, and CO2 tolerance in the global fungal pathogen Cryptococcus neoformans
Chadwick, B. J., Pham, T., Xie, X., Ristow, L. C., Krysan, D. J., & Lin, X. (2022) · eLife · doi:10.7554/elife.82563 · Cited by 35
Self-citation
Discovery of Carboline Derivatives as Potent Antifungal Agents for the Treatment of Cryptococcal Meningitis
Tu, J., Li, Z., Jiang, Y., Ji, C., Han, G., Wang, Y., Liu, N., & Sheng, C. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b01598 · Cited by 34
Strategies in the Discovery of Novel Antifungal Scaffolds
Liu, N., Wang, C., Su, H., Zhang, W., & Sheng, C. (2016) · Future Medicinal Chemistry · doi:10.4155/fmc-2016-0020 · Cited by 34
Interplay Between Drug-Induced Liver Injury and Gut Microbiota: A Comprehensive Overview
Li, G., Hou, Y., Zhang, C., Zhou, X., Bao, F., Yang, Y. H., Chen, L., & Yu, D. (2024) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2024.05.003 · Cited by 38
Fungal natural products galaxy: Biochemistry and molecular genetics toward blockbuster drugs discovery
Bhattarai, K., Bhattarai, K., Kabir, M. E., Bastola, R., & Baral, B. (2021) · Advances in genetics · doi:10.1016/bs.adgen.2020.11.006 · Cited by 35
An open label randomized controlled trial of tamoxifen combined with amphotericin B and fluconazole for cryptococcal meningitis
Ngan, N. T. T., Nhat, L. T. H., Vi, N. N., Van, N. T. T., Hoang, N. T., Anh, D. V., Trieu, P. H., Lan, N. P. H., Phu, N. H., Châu, N. V. V., et al. (2021) · eLife · doi:10.7554/elife.68929 · Cited by 33
Immunoprotection against Cryptococcosis Offered by Znf2 Depends on Capsule and the Hyphal Morphology
Lin, J., Pham, T., Hipsher, K., Glueck, N. K., Fan, Y., & Lin, X. (2022) · mBio · doi:10.1128/mbio.02785-21 · Cited by 34
Self-citation
The combination of tamoxifen with amphotericin B, but not with fluconazole, has synergistic activity against the majority of clinical isolates of Cryptococcus neoformans
Hai, T. P., Van, A. D., Ngan, N. T. T., Nhat, L. T. H., Lan, N. P. H., Châu, N. V. V., Thwaites, G. E., Krysan, D. J., & Day, J. (2019) · Mycoses · doi:10.1111/myc.12955 · Cited by 32
Small-molecule inhibitors for the Prp8 intein as antifungal agents
Li, Z., Tharappel, A. M., Xu, J., Lang, Y., Green, C. M., Zhang, J., Lin, Q., Chaturvedi, S., Zhou, J., Belfort, M., et al. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2008815118 · Cited by 31
Synergistic Therapies as a Promising Option for the Treatment of Antibiotic-Resistant Helicobacter pylori
Krzyżek, P., Paluch, E., & Gościniak, G. (2020) · Antibiotics · doi:10.3390/antibiotics9100658 · Cited by 31
Molecular typing and in vitro resistance of Cryptococcus neoformans clinical isolates obtained in Germany between 2011 and 2017
Selb, R., Fuchs, V., Graf, B., Hamprecht, A. G., Hogardt, M., Sedlacek, L., Schwarz, R., Idelevich, E. A., Becker, S. L., Held, J., et al. (2019) · International Journal of Medical Microbiology · doi:10.1016/j.ijmm.2019.151336 · Cited by 31
Effective Strategy Targeting Polymyxin-Resistant Gram-Negative Pathogens: Polymyxin B in Combination with the Selective Serotonin Reuptake Inhibitor Sertraline
Hussein, M. H., Schneider‐Futschik, E. K., Paulin, O. K. A., Allobawi, R., Crawford, S., Zhou, Q. T., Hanif, A., Baker, M. A., Zhu, Y., Li, J., et al. (2020) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.0c00108 · Cited by 31
Rising to the challenge of multiple Cryptococcus species and the diseases they cause
Idnurm, A., & Lin, X. (2015) · Fungal Genetics and Biology · doi:10.1016/j.fgb.2015.05.002 · Cited by 29
Self-citation
Congenic Strains for Genetic Analysis of Virulence Traits in Cryptococcus gattii
Zhu, P., Zhai, B., Lin, X., & Idnurm, A. (2013) · Infection and Immunity · doi:10.1128/iai.00018-13 · Cited by 28
Self-citation
Antifungal adjuvants: Preserving and extending the antifungal arsenal
Butts, A., Palmer, G. E., & Rogers, P. D. (2016) · Virulence · doi:10.1080/21505594.2016.1216283 · Cited by 29
In Vitro Activity of Sertraline, an Antidepressant, Against Antibiotic-Susceptible and Antibiotic-Resistant Helicobacter pylori Strains
Krzyżek, P., Franiczek, R., Krzyżanowska, B., Łaczmański, Ł., Migdał, P., & Gościniak, G. (2019) · Pathogens · doi:10.3390/pathogens8040228 · Cited by 26
Antifungal Drugs: The Current Armamentarium and Development of New Agents
Robbins, N., Wright, G. D., & Cowen, L. E. (2017) · ASM Press eBooks · doi:10.1128/9781555819583.ch44 · Cited by 26
Alternative treatment of fungal infections: Synergy with non‐antifungal agents
Rossato, L. L., dos Santos, M. C., Vitale, R. G., de Hoog, S., & Ishida, K. (2020) · Mycoses · doi:10.1111/myc.13203 · Cited by 27
A Family of Secretory Proteins Is Associated with Different Morphotypes in Cryptococcus neoformans
Gyawali, R., Upadhyay, S., Way, J., & Lin, X. (2016) · Applied and Environmental Microbiology · doi:10.1128/aem.02967-16 · Cited by 25
Self-citation
Efficacy of sertraline against Trypanosoma cruzi: an in vitro and in silico study
Ferreira, D. D., Mesquita, J. T., Silva, T. A. D. C., Romanelli, M. M., Batista, D. D. G. J., da Silva, C. F., da Gama, A. N. S., Neves, B. J., Melo-Filho, C. C., Soeiro, M. D. N. C., et al. (2018) · The Journal of venomous animals and toxins including tropical diseases · doi:10.1186/s40409-018-0165-8 · Cited by 25
In vitro activity of non-antibiotic drugs against Staphylococcus aureus clinical strains
Boyd, N. K., Lee, G. C., Teng, C., & Frei, C. R. (2021) · Journal of Global Antimicrobial Resistance · doi:10.1016/j.jgar.2021.09.003 · Cited by 24
The COMPASS Complex Regulates Fungal Development and Virulence through Histone Crosstalk in the Fungal Pathogen Cryptococcus neoformans
Liu, R., Chen, X., Zhao, F., Jiang, Y., Lu, Z., Ji, H., Feng, Y., Li, J., Zhang, H., Zheng, J., et al. (2023) · Journal of Fungi · doi:10.3390/jof9060672 · Cited by 25
Modulation of Replicative Lifespan in Cryptococcus neoformans: Implications for Virulence
Bouklas, T., Jain, N., & Fries, B. C. (2017) · Frontiers in Microbiology · doi:10.3389/fmicb.2017.00098 · Cited by 25
Adjunctive sertraline for asymptomatic cryptococcal antigenemia: A randomized clinical trial
Boulware, D. R., Nalintya, E., Rajasingham, R., Kirumira, P., Naluyima, R., Turya, F., Namanda, S., Rutakingirwa, M. K., Skipper, C. P., Nikweri, Y., et al. (2020) · Medical Mycology · doi:10.1093/mmy/myaa033 · Cited by 24
The Antidepressant Sertraline Induces the Formation of Supersized Lipid Droplets in the Human Pathogen Cryptococcus neoformans
Breuer, M. R., Dasgupta, A., Vasselli, J. G., Lin, X., Shaw, B. D., & Sachs, M. S. (2022) · Journal of Fungi · doi:10.3390/jof8060642 · Cited by 23
Self-citation
Searching for new antifungals for the treatment of cryptococcosis
de Sousa, N. S. O., de Almeida, J. D. R., Frickmann, H., Lacerda, M., & de Souza, J. V. B. (2023) · Revista da Sociedade Brasileira de Medicina Tropical · doi:10.1590/0037-8682-0121-2023 · Cited by 24
Mechanisms of Azole Potentiation: Insights from Drug Repurposing Approaches
Xiong, J., Lu, H., & Jiang, Y. (2025) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.4c00657 · Cited by 20
Virulence Factors as Targets for Anticryptococcal Therapy
Azevedo, R. V. D. M., Rizzo, J., & Rodrigues, M. L. (2016) · Journal of Fungi · doi:10.3390/jof2040029 · Cited by 20
Sertraline demonstrates fungicidal activity in vitro for Coccidioides immitis
Paul, S., Mortimer, R. B., & Mitchell, M. (2016) · Mycology: An International Journal on Fungal Biology · doi:10.1080/21501203.2016.1204368 · Cited by 20
Short‐course amphotericin B in addition to sertraline and fluconazole for treatment of HIV‐associated cryptococcal meningitis in rural Tanzania
Katende, A., Mbwanji, G., Faini, D., Nyuri, A., Kalinjuma, A. V., Mnzava, D., Hullsiek, K. H., Rhein, J., Weisser, M., Meya, D. B., et al. (2019) · Mycoses · doi:10.1111/myc.12995 · Cited by 20
Antifungal drug screening: thinking outside the box to identify novel antifungal scaffolds
Beattie, S. R., & Krysan, D. J. (2020) · Current Opinion in Microbiology · doi:10.1016/j.mib.2020.03.005 · Cited by 20
The Role of PET in Monitoring Therapy in Fungal Infections
Ankrah, A. O., Klein, H. C., Span, L. F. R., de Vries, E. F. J., Dierckx, R., Sathekge, M. M., & Glaudemans, A. W. J. M. (2017) · Current Pharmaceutical Design · doi:10.2174/1381612824666171213101648 · Cited by 20
Novel avenues for identification of new antifungal drugs and current challenges
Jampílek, J. (2022) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2022.2097659 · Cited by 20

Authors: Zhai, B., Wu, C., Wang, L., Sachs, M. S., & Lin, X.
Affiliations: Texas A&M University (US)
ORCID: Zhai, Bing
Wu, Cheng
Wang, Linqi
Sachs, Matthew S.
Lin, Xiaorong
Venue: Antimicrobial Agents and Chemotherapy
Publisher: American Society for Microbiology
Published: 2012-07
Volume: 56
Issue: 7
Pages: 3758-3766
ISSN: 0066-4804 (ISSN-L)
1098-6596
DOI: 10.1128/aac.00212-12
PMC: PMC3393448
OpenAlex: W2172160469
Cited by: 205
References: 44
Citations by year: 2026: 12 · 2025: 13 · 2024: 19 · 2023: 18 · 2022: 18 · 2021: 13 · 2020: 21 · 2019: 24 · 2018: 12 · 2017: 15 · 2016: 18 · 2015: 9 · 2014: 6 · 2013: 5 · 2012: 2
FWCI: 5.25
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: journals.asm.org/non-commercial-tdm-license (tdm)
Locations: Antimicrobial Agents and Chemotherapy (publishedVersion)
Europe PMC (PubMed Central) (publishedVersion)
PubMed Central (publishedVersion)
PubMed (publishedVersion)
OakTrust (Texas A&M University Libraries) (submittedVersion)
Funders: American Heart Association
Johns Hopkins University
National Institute of General Medical Sciences (R01GM47498, R01GM047498)
National Institute of Allergy and Infectious Diseases (R01AI097599)
Topics: Health Sciences › Medicine › Infectious Diseases › Fungal Infections and Studies
Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
Life Sciences › Agricultural and Biological Sciences › Plant Science › Fungal Plant Pathogen Control
Keywords: sertraline, Cryptococcus neoformans, cryptococcosis, cryptococcal meningitis, antifungal activity, fluconazole, drug synergy, drug repurposing, antidepressants, Candida, protein synthesis inhibition, blood-brain barrier, systemic fungal infection
MeSH terms: Animals, Antidepressive Agents, Cryptococcosis, Cryptococcus neoformans, Female, Microbial Sensitivity Tests, Saccharomyces cerevisiae, Fluconazole, Sertraline, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

The Antidepressant Sertraline Provides a Promising Therapeutic Option for Neurotropic Cryptococcal Infections

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks